Sugammadex, SNaPP, and Postoperative Pulmonary Complications
When a large, pragmatic trial compares the two drugs we reach for most often at the end of a case, I pay close attention, even when the absolute difference appears modest on paper. The SNaPP trial, published in The Lancet Respiratory Medicine and summarized for clinicians by Pulmonology Advisor, asked whether reversing aminosteroid neuromuscular blockade with sugammadex, rather than neostigmine, lowers postoperative pulmonary complications or death after major abdominal or thoracic surgery.
In brief, among nearly 3,500 adults aged 40 and older, the composite of pulmonary complications or death occurred in about 19% of patients who received sugammadex and in about 21.5% of those who received neostigmine (risk ratio roughly 0.88). Most of that difference reflected less atelectasis. Pneumonia, aspiration, mortality, unplanned ICU or high-dependency admission, days alive and at home, and later quality of life did not differ meaningfully. The pattern is consistent with what many of us already observe in the OR: sugammadex often provides a cleaner, more predictable reversal and a smoother path to extubation, yet it offers no guarantee against every postoperative lung event.
How I read this as a clinician
SNaPP strengthens the case for sugammadex as a reasonable first-line choice when we are reversing rocuronium or vecuronium in higher-risk abdominal and thoracic cases, particularly when residual weakness or delayed emergence would be costly. In my view, it does not mean that every healthy outpatient now “requires” sugammadex, nor does it render neostigmine obsolete when quantitative monitoring and appropriate dosing are used carefully. Cost, availability, and patient-specific factors still matter.
The atelectasis finding is statistically real, although its clinical weight is softer. Imaging-defined atelectasis is common after major surgery, and whether this component of the composite translates into fewer long-term harms remains uncertain. I place more emphasis on the process measures beneath the headline result: complete reversal, timely return of airway reflexes, and the avoidance of residual paralysis in patients who already carry pulmonary risk.
Implications for practice
SNaPP showed a small but statistically significant reduction in the composite of postoperative pulmonary complications or death with sugammadex compared with neostigmine after major abdominal or thoracic surgery. Most of that reduction came from less atelectasis, and rates of pneumonia, aspiration, and death were similar. Because the absolute benefit was modest, the trial should not be read as proof that sugammadex prevents all serious pulmonary morbidity.
Whichever reversal agent is chosen, quantitative neuromuscular monitoring remains essential. I favor sugammadex when residual weakness would be especially hazardous, as in thoracic or abdominal cases, older patients, and those with limited reserve, while still individualizing the decision for cost, indication, and monitoring data.
Source
- Leslie K, et al. Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (SNaPP). The Lancet Respiratory Medicine. Full text
- Pulmonology Advisor coverage: Postoperative Pulmonary Complications: Sugammadex Outperforms Neostigmine
This post is clinician commentary for educational discussion. It is not medical advice for any reader’s personal care. Anesthesia and perioperative decisions should be made with the treating clinician based on the individual patient’s circumstances.